RecruitingNot ApplicableNCT07195994

A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes

A Randomized, Single-blind, Controlled, Parallel Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes

Sponsor

QuickSilver Scientific

Enrollment

90 participants

Start Date

Feb 5, 2026

Study Type

INTERVENTIONAL

Conditions

Prediabetes / Type 2 Diabetes

Summary

This is a randomized, single-blind, controlled, parallel clinical trial to examine the efficacy and safety of AMPK Charge+® with and without use of semaglutide on glycemic response in adults with prediabetes or Type 2 Diabetes. The main question it aims to answer is: What is the difference in change in fasting blood glucose and insulin, and hemoglobin A1c (HbA1c) from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide? Participants will consume AMPK Charge+® with or without semaglutide injections and will be evaluated for glycemic response parameters.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing whether a new investigational product — used with or without the GLP-1 drug semaglutide (Ozempic/Wegovy) — can improve blood sugar control in adults with prediabetes or Type 2 diabetes. **You may be eligible if...** - You are 18 years of age or older with prediabetes or Type 2 diabetes - Female participants must be post-menopausal, surgically sterilized, or using an approved contraceptive method for at least 3 months before the study - Male participants must meet the study's fertility and contraception requirements - You are willing to follow the study protocol for the duration of the trial **You may NOT be eligible if...** - You are a woman of childbearing potential who is pregnant (confirmed by a baseline urine pregnancy test) or not using an approved contraceptive method - You are a man who does not meet the contraception requirements - Your blood sugar control or other health parameters fall outside the study's required ranges Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTAMPK Charge+®

Participants will be instructed to consume 1 teaspoon (5 mL) on an empty stomach before breakfast and 1 teaspoon on an empty stomach in the afternoon and to hold the product in the mouth for approximately 30-90 seconds before swallowing starting on Day 1.

DIETARY_SUPPLEMENTAMPK Charge+® with semaglutide

Participants will be instructed to use the provided measuring tool to take 1 teaspoon (5 mL) on an empty stomach before breakfast and 1 teaspoon on an empty stomach in the afternoon and to hold the product in the mouth for approximately 30-90 seconds before swallowing starting on Day 1. Participants will be instructed to administer subcutaneous semaglutide once per week beginning with a dose of 0.25 mg for four weeks at which point participants will be instructed to increase the dose to 0.5 mg per week for the remainder of the study period.

Locations(1)

KGK Science Inc.

London, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07195994

Related Trials

Whey Protein Ingestion and Glucose Control in Pre- and Post Diabetic Individuals

NCT066941551 location

Diabetes Prevention in Hispanic Adults Using Constant Glucose Monitors

NCT068647281 location

Effects of Exercise Prediabetic Individuals

NCT068312662 locations